- Visit Vietnam Insider’s homepage for more stories
Trials for Nanocovax, a made-in-Vietnam Covid-19 vaccine, have shown positive results.
Between December last year and April this year, Vietnam completed the first and second stage of human trials of Nanocovax with the participation of more than 600 volunteers.
All of the vaccinated volunteers have developed antibodies against Covid-19 at different levels.
Nanogen Pharmaceutical Biotechnology JSC, the vaccine producer, has also sent serum samples from the volunteers to research facilities in Vietnam to assess immunity against India’s Delta variant.
The third phase of human trials of the vaccine would require around 13,000 volunteers split into two groups: one injected with the 25 mcg doses and the other receiving placebos. Recently, 1,000 volunteers were given the first shot of the vaccine in the phase.
Two months after the third trial phase completes, the Ministry of Health would seek the government’s approval for the licence of the vaccine’s circulation.
According to Ho Nhan, General Director of Nanogen Pharmaceutical Biotechnology JSC, from now to October this year, Nanocovax vaccine productivity would reach 10-12 million doses per month and the figure would rise to 30-50 million doses for both domestic use and export.
A dose of this vaccine can be priced at VND120,000 (USD5.21).
Nanogen Pharmaceutical Biotechnology JSC started producing the Nanocovax vaccine from May last year following the order from the Ministry of Science and Technology.
Based on the results of the first and second phases, experts are optimistic that if the tests are successful, the third phase of the trial would be completed at the end of the third quarter, shortening the research by three months compared to previously planned.
This article was originally published in Dtinews